Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03582033 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
A Phase 1 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 83
- Enrollment target
NCT03582033 is a Phase 1 study that was terminated before completion, run by Seagen. The registered enrollment target is 83 participants.
The verdict
NCT03582033, a Phase 1 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 83 participants
- Enrollment target
Study Summary
This trial will study SEA-BCMA to find out whether it is an effective treatment for multiple myeloma (MM) and what side effects (unwanted effects) may occur. The study will have several parts. In Parts A and B, participants get SEA-BCMA by itself. This part of the study will find out how much SEA-BCMA should be given for treatment and how often. It will also find out how safe the treatment is and how well it works. In Part C of the study, participants will get SEA-BCMA and dexamethasone. In Part D, participants will get SEA-BCMA, dexamethasone, and pomalidomide. Dexamethasone and pomalidomide are both drugs that can be used to treat multiple myeloma. These parts of the study will find out whether these drugs are safe when used together.
Interventions
- DRUG dexamethasone
- DRUG pomalidomide
- DRUG SEA-BCMA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2023-11-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03582033
The ClinicalTrials.gov registry entry for NCT03582033 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which dexamethasone is the first listed.
NCT03582033 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03582033 about?
NCT03582033 is a clinical study titled "A Safety Study of SEA-BCMA in Patients With Multiple Myeloma". This trial will study SEA-BCMA to find out whether it is an effective treatment for multiple myeloma (MM) and what side effects (unwanted effects) may occur. The study will have several parts. In Parts A and B, participants get SEA-BCMA by itself. This part of the study will find out how much SEA-B...
What is the current status of trial NCT03582033?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2018-11-01. Estimated completion is 2023-11-09.
What interventions are being tested in trial NCT03582033?
The interventions under investigation include: dexamethasone (DRUG), pomalidomide (DRUG), SEA-BCMA (DRUG).
Who is sponsoring clinical trial NCT03582033?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.